MaxCyte Historical Financial Ratios
MXCT Stock | USD 3.63 0.08 2.25% |
MaxCyte is lately reporting on over 97 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 54.74 will help investors to properly organize and evaluate MaxCyte financial condition quickly.
MaxCyte |
About MaxCyte Financial Ratios Analysis
MaxCyteFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate MaxCyte investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on MaxCyte financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across MaxCyte history.
MaxCyte Financial Ratios Chart
Add Fundamental
Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Earnings Yield
The inverse of the price-to-earnings ratio, representing the percentage of each dollar invested in the stock that was earned by the company.Most ratios from MaxCyte's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into MaxCyte current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MaxCyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.At this time, MaxCyte's Sales General And Administrative To Revenue is comparatively stable compared to the past year. Cash Per Share is likely to gain to 1.71 in 2024, whereas Operating Cash Flow Per Share is likely to drop (0.22) in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 2.0 | 17.46 | 6.38 | 6.7 | Days Of Inventory On Hand | 520.83 | 614.31 | 941.29 | 988.35 |
MaxCyte fundamentals Correlations
Click cells to compare fundamentals
MaxCyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
MaxCyte fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 44.34 | 45.13 | 27.24 | 12.55 | 11.76 | 11.17 | |
Ptb Ratio | 70.49 | 35.54 | 3.51 | 2.19 | 2.09 | 2.2 | |
Days Sales Outstanding | 54.77 | 72.14 | 74.06 | 92.15 | 51.08 | 54.74 | |
Free Cash Flow Yield | (0.0105) | (0.009191) | (0.0157) | (0.0599) | (0.0523) | (0.0497) | |
Operating Cash Flow Per Share | (0.16) | (0.13) | (0.12) | (0.15) | (0.21) | (0.22) | |
Stock Based Compensation To Revenue | 0.081 | 0.0945 | 0.23 | 0.27 | 0.34 | 0.36 | |
Pb Ratio | 70.49 | 35.54 | 3.51 | 2.19 | 2.09 | 2.2 | |
Ev To Sales | 43.97 | 44.68 | 26.0 | 12.66 | 11.08 | 10.53 | |
Free Cash Flow Per Share | (0.22) | (0.18) | (0.16) | (0.33) | (0.25) | (0.26) | |
Roic | (0.71) | (0.31) | (0.073) | (0.0904) | (0.21) | (0.22) | |
Inventory Turnover | 0.68 | 0.64 | 0.7 | 0.59 | 0.39 | 0.37 | |
Net Income Per Share | (0.24) | (0.18) | (0.22) | (0.19) | (0.37) | (0.35) | |
Days Of Inventory On Hand | 540.64 | 569.31 | 520.83 | 614.31 | 941.29 | 988.35 | |
Payables Turnover | 1.2 | 3.11 | 2.0 | 17.46 | 6.38 | 6.7 | |
Capex To Revenue | 0.0588 | 0.0792 | 0.11 | 0.42 | 0.0896 | 0.0602 | |
Cash Per Share | 0.3 | 0.5 | 2.81 | 2.24 | 1.63 | 1.71 | |
Pocfratio | (108.92) | (134.47) | (86.46) | (37.56) | (22.38) | (23.5) | |
Interest Coverage | (18.24) | (13.39) | (17.42) | (215.61) | (247.95) | (235.55) | |
Capex To Operating Cash Flow | (0.14) | (0.24) | (0.36) | (1.25) | (0.17) | (0.18) | |
Pfcf Ratio | (95.17) | (108.8) | (63.62) | (16.7) | (19.12) | (20.08) | |
Days Payables Outstanding | 305.15 | 117.43 | 182.16 | 20.9 | 57.19 | 54.33 | |
Income Quality | 0.68 | 0.74 | 0.56 | 0.63 | 0.57 | 0.81 | |
Roe | (0.72) | (1.0) | (0.38) | (0.0766) | (0.0779) | (0.16) | |
Ev To Operating Cash Flow | (108.01) | (133.12) | (82.52) | (37.9) | (21.1) | (22.16) | |
Pe Ratio | (70.62) | (93.41) | (45.88) | (28.07) | (12.8) | (13.44) | |
Return On Tangible Assets | (0.45) | (0.24) | (0.0708) | (0.069) | (0.14) | (0.15) | |
Ev To Free Cash Flow | (94.38) | (107.71) | (60.72) | (16.85) | (18.03) | (18.93) | |
Earnings Yield | (0.0142) | (0.0107) | (0.0218) | (0.0356) | (0.0781) | (0.0742) | |
Net Debt To E B I T D A | 0.69 | 1.19 | 2.51 | (0.24) | 0.63 | 0.66 | |
Current Ratio | 2.62 | 3.9 | 17.32 | 16.35 | 10.65 | 11.18 | |
Receivables Turnover | 6.66 | 5.06 | 4.93 | 3.96 | 7.15 | 6.34 | |
Graham Number | 1.14 | 1.4 | 3.81 | 3.31 | 4.31 | 4.53 | |
Debt To Equity | 0.41 | 0.36 | 0.15 | 0.003334 | 0.003 | 0.00315 | |
Capex Per Share | 0.0225 | 0.0298 | 0.0423 | 0.18 | 0.0358 | 0.0235 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.